TY  - JOUR
AU  - Bermejo de Las Heras, Begoña
AU  - Cortes Ramon Y Cajal, Javier
AU  - Galve Calvo, Elena
AU  - de la Haba Rodriguez, Juan
AU  - Garcia Mata, Jesus
AU  - Moreno Anton, Fernando
AU  - Pelaez Fernandez, Ignacio
AU  - Rodriguez-Lescure, Alvaro
AU  - Rodriguez Sanchez, Cesar A
AU  - Ruiz-Borrego, Manuel
AU  - Remak, Edit
AU  - Barra, Magdolna
AU  - Rivero, Maria
AU  - Soto Alvarez, Javier
PY  - 2018
DO  - 10.1136/ejhpharm-2017-001453
SN  - 2047-9956
UR  - http://hdl.handle.net/10668/15115
T2  - European journal of hospital pharmacy : science and practice
AB  - The study aimed to estimate the burden of metastatic breast cancer (mBC) in Spain over 5 years. An incidence-based cost-of-illness model was developed in which a cohort of patients with mBC was followed from the diagnosis of metastatic disease over...
LA  - en
PB  - BMJ Group
KW  - Costs of illness
KW  - Direct costs
KW  - Metastatic breast cancer
KW  - Resource utilisation
KW  - Treatment patterns
KW  - Antineoplastic combined chemotherapy protocols
KW  - Breast neoplasms
KW  - Cohort studies
KW  - Cost of illness
KW  - Female
KW  - Follow-up studies
KW  - Health xare xosts
KW  - Humans
KW  - Neoplasm metastasis
KW  - Receptor, ErbB-2
KW  - Spain
KW  - Survival rate
KW  - Triple negative breast neoplasms
TI  - The economic burden of metastatic breast cancer in Spain.
TY  - research article
VL  - 27
ER  -